Saw Palmetto for Hair Loss — Supplements
Serenoa repens extract with 10-trial meta-analysis evidence for 30% DHT reduction; mild 5α-reductase inhibition without systemic sexual side effects of finasteride.
Overview
Saw palmetto (Serenoa repens) is a fan palm native to the southeastern United States whose berry extract has been studied extensively for benign prostatic hyperplasia (BPH) and, more recently, androgenetic alopecia (AGA). Its mechanism as a hair loss treatment parallels that of finasteride — inhibition of 5α-reductase enzyme activity, reducing conversion of testosterone to the more potent androgen dihydrotestosterone (DHT). A 2020 systematic review and meta-analysis of 10 clinical trials (n=502) confirmed saw palmetto reduces serum DHT by approximately 30% compared to placebo. A 2002 randomized controlled trial (Prager et al.) demonstrated that saw palmetto extract (320 mg/day) improved hair growth in 60% of men with mild-to-moderate AGA over 24 weeks, compared to 68% for finasteride — making saw palmetto the only botanical supplement with a head-to-head comparison against a pharmaceutical 5-ARI. A 2020 observational study comparing 1 mg finasteride to 320 mg saw palmetto over 24 months showed similar photographic improvement between groups in men preferring to avoid finasteride's sexual side effects. Saw palmetto inhibits both type I and type II 5α-reductase, and also demonstrates anti-inflammatory properties via inhibition of COX-2 and 5-LOX pathways, which may contribute additional benefit in pattern hair loss, where DHT-driven follicular inflammation is a key pathogenic mechanism. Importantly, saw palmetto does not cause the sexual dysfunction or post-finasteride syndrome seen with pharmaceutical 5-ARIs and does not significantly suppress serum PSA — an important consideration for prostate cancer screening accuracy.
Indications
- Androgenetic alopecia (AGA) — male and female pattern hair loss
- Hair loss prevention as alternative to finasteride (sexual side-effect avoidance)
- Benign prostatic hyperplasia (BPH) adjunctive support
- PCOS-related androgen excess (off-label, limited evidence)
Mechanism of Action
Saw palmetto's lipophilic extract — rich in free fatty acids (lauric acid, oleic acid, myristic acid) and beta-sitosterol — inhibits both type I (expressed in sebaceous glands, scalp) and type II (expressed in hair follicle dermal papilla) 5α-reductase isoenzymes, reducing DHT formation from testosterone. The dual isoenzyme inhibition profile resembles dutasteride more than finasteride (which is type II-selective)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Saw palmetto lipophilic extract (standardized to 85-95% fatty acids) | 320 mg | Once daily with food | Only standardized lipophilic extract has clinical evidence; dry herb capsules and teas are ineffective |
| Saw palmetto extract (split dosing) | 160 mg | Twice daily with meals | Alternative twice-daily protocol; same total dose but may improve tolerability |
Safety & Contraindications
- Excellent tolerability — no significant sexual side effects reported in clinical trials, unlike finasteride/dutasteride
- Mild GI upset possible (nausea, diarrhea) — take with food to minimize
- Does not significantly suppress PSA levels — does not interfere with prostate cancer screening (advantage over finasteride)
- Anti-platelet effects documented — discontinue 2 weeks before surgery; use caution with anticoagulants
- Theoretical CYP3A4 interaction — may increase levels of substrates; clinical significance uncertain at standard doses
- Avoid in pregnancy — teratogenic in animal studies (anti-androgenic effects on male fetal development)
- May affect hormonal contraceptive efficacy theoretically — clinical significance unknown
- Product quality highly variable — lipophilic extract standardized to 85-95% fatty acids and sterols is required; non-standardized products are ineffective